HopeStage
Back to all studies
TerminatedNCT03481959

Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity

Medication studyAges 12–25FranceADHD
The study in practice

Understand this study

Who could participate?

Listed age limits: 12 years to 25 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 7, 2019
Recruitment status
Terminated
Enrollment listed in the registry
3
Sponsor
Assistance Publique - Hôpitaux de Paris
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug, Other
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France
Age range
From 12 Years to 25 Years
Official registry ID
NCT03481959
Official title
Show the full official title

Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity

Recruitment & locations

Terminated

Paris

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Assistance Publique - Hôpitaux de Paris.

Does this study involve medication?

Yes. The study involves medication, including Methylphenidate.

Who can participate?

Listed age limits: 12 years to 25 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies